

September 30, 2024



PDRadiopharma Inc.

Launch of Medical DX (Digital Transformation) Solutions Bridgea TIMER Guide™ and “onti-d”

TOKYO, JAPAN – September 30, 2024 - PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo, Japan, hereinafter “PDRadiopharma”) announced the launch of two Medical Digital Transformation (DX) systems “Bridgea TIMER Guide” and “onti-d” to provide a further operational support for healthcare professionals by leveraging data and digital technologies.

① **Bridgea TIMER Guide:** Time management system of PET (Positron Emission Tomography) examination

The “Bridgea TIMER Guide” is an optional enhancement to the “Bridgea TIMER” system, which facilitates the sharing of PET scan time management information among healthcare professionals, enabling real-time monitoring of patient status throughout the examination.

The “Bridgea TIMER Guide” provides patients with step-by-step instructions through audio and visual displays, guiding them from preparation and administration to imaging and the completion of the examination. This system offers remote patient guidance, improving operational efficiency for healthcare professionals and helping reduce radiation exposure.

② **onti-d:** Radiopharmaceutical Operational Support System

The “onti” system is an advanced information platform designed to support the electronic recording, management, and optimization of radiation exposure doses. The “onti” includes operational support features such as patient information acquisition, prevention of administration errors, automatic calculation of administered doses, and the creation of radiopharmaceutical usage records, those are not equipped with conventional radiation dose management systems.

PDRadiopharma will continue to actively promote medical DX solutions that not only improve the operational efficiency of healthcare providers but also contribute to reducing the risk of medical accidents by digitalizing the management of radiation exposure doses due to the administration of radiopharmaceuticals, including its conventional products, and lead the industry as a pioneer in medical DX.

About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 21 radiodiagnostic products (spanning both SPECT and

PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit www.pdradiopharma.com.

Inquiries:

PDRadiopharma Inc.

Contact: Noriko Tanaka, General Affairs

Email: s-info-hq@pdradiopharma.com